CompletedNCT00145444
Ziprasidone compared with olanzapine for recent-onset psychosis
About this title
Read the official source — NCT00145444Medication studyAges 18–40Belgium + NetherlandsSchizophrenia
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 40 years. Other eligibility criteria applied.
- Listed locations
- Antwerp and 6 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateMarch 2003
- Recruitment status
- Completed
- Enrollment listed in the registry
- 100
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Belgium, Netherlands
- Age range
- From 18 Years to 40 Years
- Official registry ID
- NCT00145444
- Official title
Show the full official title
A Multicenter, Double-Blind, Randomized Trial Of Ziprasidone (80 - 160 Mg) Versus Olanzapine (10 - 20 Mg) In Patients With Recent-Onset Schizophrenia, Schizoaffective And Schizophreniform Disorder.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Antwerp, Belgium · Duffel, Belgium · Kortenberg, Belgium
4 more locations
- Ermelo, Netherlands
- Groningen, Netherlands
- Nijmegen, Netherlands
- Utrecht, Netherlands
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Did this study involve medication?
Yes. The study involved medication, including olanzapine and ziprasidone.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 40 years. Other eligibility criteria applied.
